Liquid Dosage
Protein-based therapeutics are increasingly being developed as new chemical entities in the pharmaceutical and life science industries. Unlike small molecules, which are typically synthesized using chemical processes, most proteins need to be processed in living systems, mostly by recombinant DNA technology. The proteins can then be produced in their functional form (quaternary structure), rather than by microbial biosynthesis (bacteria/yeast), substantially reducing the downstream stages of the process.
As the demand for large-volume products increases, so does the requirement for higher capacity reactors (up to 20,000 L) to realize economies of scale. GEA has responded to the changing needs of biopharmaceutical manufacturers and developed improved technology solutions to optimize both upstream and, with increasing titers, downstream processing, in terms of time and cost efficiency.
Based on its history of innovation and process development, GEA has a thorough working knowledge of therapeutic protein production and has used this competence to design better media and feeding strategies, optimize the fermentation stage and enhance physicochemical conditions during the manufacturing process.
A leading international supplier of integrated process systems, our extensive portfolio of products, technologies and services includes standard and customized fermenters, separators and entire production lines, as well as plant for the production, storage and distribution of clean utilities. Systems for the preparation of media, fluid management, cell cultivation and purification are also part of our global scope of supply.
As a competent manufacturer of complete plant for the life science industries, GEA is a full-service provider of solutions that meet your exact requirements and specifications. From planning, development and installation to qualification and maintenance, our experienced engineers will collaborate with your project team to supply innovative and efficient process solutions for your applications.
Showing 4 of 12
Aseptic valves face exceptionally high demands within UltraClean and Aseptic processes. You can be assured that they all provide highest quality in terms of hygienic design and sustainability.
GEA separators are designed for liquid-based applications. Using centrifugal force, they are used for separating suspensions consisting of two or more phases of different densities, i.e. they can be used for liquid-liquid separation, for liquid-liquid-solid separation or for liquid-solid separation. They are equally as effective at separating liq...
Innovative CIP concepts of GEA meet comprehensive high standards. Our experts guarantee product safety at every point of the process. Every upgrade is adapted to individual local conditions and customer requirements and leads to noticeable savings.
GEA compression heads are the homogenizer pulsing core since they activate the homogenization process pumping the product at high pressure until it flows inside the homogenizing valve.
Whether it’s a fad or the future, 100% vial traceability is becoming an increasingly important consideration in the pharmaceutical freeze drying industry. Keeping a close eye on developments is GEA. We’re investigating possible solutions and, what’s more, we have the experience, expertise and know-how to implement them.
There was a time when the phrases ‘non-alcoholic beer’ and ‘tastes good’ were seldom used together in the same sentence, particularly by consumers. But low-proof and alcohol-free beers have come a long way – many of them now refreshing drinks in their own right – thanks in no small part to technology from GEA.
At GEA, our commitment to engineering for a better world fuels our pursuit of innovative solutions that enhance patient care and safety. One of our most promising ventures in recent years is aseptic spray drying – a technology that promises to revolutionize pharmaceutical manufacturing.